Global Fatty Liver Day, Thursday, June 11, 2026. Steatotic (fatty) liver disease is now the most common chronic liver condition in the world, projected to affect 357 million people by 2030. Patients face increased risk of adverse cardiovascular events and the development of chronic kidney disease. This makes fatty liver disease one of the most significant drivers of cardiometabolic risk we face today. Yet awareness, diagnosis, and access to care continue to lag behind its impact. Perspectum is proud to mark another year of contributing to this global effort. Through quantitative MRI, multi-organ assessment, and clinically validated tools like LiverMultiScan, we're working with health systems, pharma partners, and clinical researchers to bring earlier, more precise insight to patients living with, or at risk of, liver disease. The work isn't finished. Earlier detection, sharper stratification, and the insight clinicians need to act sooner. Thank you to the Global Liver Institute and the worldwide partner community driving this conversation forward. #Perspectum #GlobalFattyLiverDay #MASLD #MASH #LiverHealth #PrecisionMedicine

Season of Science: Twelve Papers Advancing Diagnostic Imaging Day 9 Today’s feature focuses on the economic impact of imaging in the era of new MASH therapeutics. With the FDA’s approval of resmetirom, health systems face an urgent question: How do we diagnose and monitor patients accurately and affordably at scale? This analysis, published in the Journal of Medical Economics, evaluated three diagnostic and monitoring pathways, cT1, VCTE, and liver biopsy, across both Veterans Health Administration (VHA) and Medicare populations. The findings show that cT1 provides the least costly and most clinically appropriate approach for widespread adoption of resmetirom.Key findings: 1. cT1 resulted in the lowest per-patient cost across both health systems. • VHA: $7,022 per patient with cT1 vs. $7,286 (biopsy) and $28,509 (VCTE). • Medicare: $11,866 per patient with cT1 vs. $15,488 (biopsy) and $27,539 (VCTE). (Tables 2 & 4) 2. VCTE produced the highest false-positive rates, leading to large numbers of inappropriate treatment allocations and dramatically inflated costs. • In VHA modelling, VCTE misallocated over 1 million patients to treatment incorrectly (Fig. 2B). • cT1 appropriately ruled out 88% of non-eligible patients, comparable to biopsy but safer and far less costly. 3. For monitoring response to therapy, cT1 clearly outperformed VCTE. • cT1 correctly identified 67% of non-responders, compared with just 21% using VCTE. • This reduces unnecessary drug spend and protects patients from ineffective treatment. 4. Budget impact modelling remained robust across multiple scenarios. • Even when resmetirom drug costs doubled, cT1 still had the lowest budget impact. • Reducing monitoring frequency to once annually further amplified savings with cT1. (Tables 3 & 5) 5. Biopsy, is invasive and costly for widespread, repeated use, reinforcing the need for noninvasive, scalable tools such as cT1. Why this matters: As MASH enters the era of approved therapeutics, precision in diagnosis and monitoring becomes critical, not only for clinical effectiveness but also for sustainable health system economics. This study positions cT1 as the leading imaging biomarker for supporting resmetirom adoption in large public payer systems, offering both clinical accuracy and major budget savings. Read the full paper here: tandfonline.com/doi/10.1080/… Tomorrow we continue our journey through the year’s most influential imaging research. #Perspectum #SeasonOfScience #Resmetirom #HealthEconomics #LiverMultiScan #PrecisionMedicine

$ALT Altimmune $NVO plans to show real-world evidence that NITs usefully track MASH Will they show post-hoc correlation between NIT changes and biopsy outcomes from ESSENCE? This is relevant to $ALT pemvidutide as a positive read-through, if a market leader shows NITs track treatment benefit, validates NITs as credible endpoints Wider acceptance of NITs in clinic reduces biopsy dependence - ie ALT 24w & coming 48w data $NVO has been building partnerships and engaging across key NITs (FibroScan/TE, MRE/MRI-PDFF, LiverMultiScan/cT1, ELF, Pro-C3, NIS4, FIB-4), plus working with LITMUS, NIMBLE Presenting real-world evidence on NITs in MASH at AASLD 2025 - evaluating the benefits 👇👇👇

Day 2 #AACE2025 is here, and our ePoster sessions are LIVE! 📊 📍 Catch us in the ePoster Gallery to explore: Change in cT1 following interventions in MASLD: A systematic review & meta-analysis Liver disease activity measured with quantitative MRI is associated with new-onset diabetes & liver events in the general population and in those living with obesity Let’s Learn. Share. Advance. together! #Perspectum #LiverMultiScan #QuantitativeMRI #MASLD

Congratulations to the authors featured on the @JHepatology cover! Their stunning LiverMultiScan image highlights groundbreaking findings: reductions in cT1 and PDFF liver fat content reflect treatment-induced histological improvements in MASH. A big step forward in non-invasive liver monitoring and response to treatments.👏 #MASH journal-of-hepatology.eu/art…

At the BASL conference in Harrogate, England with @Statofish (Louise Campbell) MSc (AP), RMN, RN, FRCP and we did a VCTE guided Fibroscan to see if my (@betelm) numbers have changed from May 2024 when I had a 254 CAP score. I did just eat, so Fibrosis score slightly elevated). Yesterday I had a @PerspectumGroup LiverMultiScan and results showed a healthy normal liver. So, they did correlate. It is an incredible feeling to know that, although it is very difficult, over time, you can improve your liver health, and seeing it on a screen makes it more real. @AASLDtweets, @EASLnews, @CASLupdates, @GlobalLiver, @EuropeLiver, @FrancqueSven, @LiverPatients, @Echosens, @PerspectumGroup

Want to know more about the research that helps LiverMultiScan and our other products improve the accuracy of diagnosis and precision of disease monitoring? Meet Perspectum's experts at booth 4565. Find out about our seamless integration with physician workflows. #RSNA23 #SaaS

興味深い！！！ ｢米国でFDA承認されたAI医療機器がどれくらい臨床導入されているか｣ ･ FDA承認されたAIデバイスは500を超えている ･ しかし、承認後にこれらのデバイスが実際にどこでどのくらいの頻度で使用されるかについてはほとんど知られていない ･ CPTコードを追跡し、米国における医療 AI デバイスの導入と使用状況を体系的に定量化 ＜図: 上位AI医療機器とその地理的導入分布＞ 1位 HeartFlow Analysis 心血管の狭窄（FFR） 2位 LuminetricsCore 糖尿病網膜症診断 3位 Cleerly 心血管の狭窄 4位 Perspectum LiverMultiScan 肝臓のMR診断支援 onepub-media.nejmgroup-produ…

And then there were 4: There’s AI that is approved and AI that pays the bills. Which one are you using in your hospital or imaging center? Great work by @imagewire to dissect the Kevin Wu @NEJM_AI article (see below) for CPT reimbursement from Nov 2020 to Jul 2022. Findings 👇🏼 💥over 500 FDA approved AI systems in healthcare, most in Radiology 💥16 were CPT (not just NTAP) and used in both hospital/outpatient settings 💥only 4 services were reimbursed with success >1000 claims. 1. @HeartFlow 2. LumineticsCore 3. @Cleerlyhealth 4. Perspectum LiverMultiscan Takeaway: Align yourself with a Radiologist who can help you in Cardiac imaging, workflow mgt and use of cardiac imaging AI…

Our latest review on @PerspectumGroup MRI LiverMultiScan software as a marker of liver health, in the surgical management of CRLM. 🔍Exploring its role in patient selection and optimising FLR @Adam_Frampton1 @TELL_Starlinger @somaiaharoori @DamianJMole mdpi.com/2072-6694/15/19/486…

Expert review published in Liver International proposed integrating LiverMultiScan in the clinical care pathway for NAFLD. cT1 was identified as a key biomarker for risk-stratifying patients with high-risk NASH to improve patient outcomes. Read more: onlinelibrary.wiley.com/doi/… #NASH

We would like to say thank you to our amazing speakers – Dr Nadege Gunn, Dr Mukesh Harisinghani and Dr Lawrence Tanenbaum who presented LiverMultiScan in the Management of Diffuse Liver Disease at #SAR23. If you missed the symposium you can learn more at Perspectum.com

Please join our faculty at #SAR23, as they present LiverMultiScan; how it works, how it integrates into Radiology settings and how newest Clinical Guidelines incorporate LiverMultiScan into diagnostic pathways.

Thrilled to be at #APASL2023 to highlight studies showing how LiverMultiScan could risk-stratify patients with NASH, and Bayesian networks could identify parameters that influence liver regeneration. Join us at APASL to hear more. #MedTech Read more: perspectum.com/for-researche…

Lung Cancer Prediction (RevealDX/Optellum: 0722T & 0721T), Koios (AI for US), LiverMultiScan (Perspectum), & few others got New Tech APC placement for 2023. We're partnering with a few of these co's to accelerate their path to market @Sirona_Medical sironamedical.com/sirona-med…

Thrilled to share Dr. Carlos Duncker’s highlights from AASLD including talks by Dr. Naim Alkhouri and Prof. Stephen Harrison describing the utility of LiverMultiScan for patients with NAFLD/NASH and beyond. Read our Physician Education Hub: perspectum.com/physician-edu… #liverdisease

Beautiful color images showing improvement in fibro-inflammation by cT1 measurement after weight loss from bariatric surgery. @PerspectumGroup @LiverMultiScan #livertwitter #endotwitter

In CALIBRATE study we access change at 12 weeks and 12 months from baseline in liver and other intra-abdominal organ health. LiverMultiScan provides three metrics in one single scan that represent the amount of fibro-inflammation, fat, and iron in your liver. #calibratestudy

Excited to showcase our study results at the #UEGWeek Congress 2022, which found that LiverMultiScan could be used as a noninvasive alternative to painful, repeat liver biopsies for monitoring children with AIH. Meet Dr Shumbayawonda at UEG or learn more: tinyurl.com/32kvk4pt

Our abstract showing that LiverMultiScan could be used as a noninvasive alternative to painful, repeat liver biopsies for monitoring children with AIH has been accepted for oral and poster presentations at the #UEGWeek 2022. Learn more: ow.ly/Vght50KRgMx)